scholarly journals Synthesis and in vitro studies of PLGA-DTX nanoconjugate as potential drug delivery vehicle for oral cancer

2018 ◽  
Vol Volume 13 ◽  
pp. 67-69 ◽  
Author(s):  
Parul Gupta ◽  
Manjri Singh ◽  
Rajiv Kumar ◽  
Jodi Belz ◽  
Rishi Shanker ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Oral Cancer ◽  
In Vitro Studies ◽  
Potential Drug ◽  
Delivery Vehicle ◽  
Drug Delivery Vehicle

pH-Sensitive Polymer Nanospheres for Use as a Potential Drug Delivery Vehicle

2007 ◽  
Vol 8 (11) ◽  
pp. 3401-3407 ◽  
Author(s):  
Jua Jung ◽  
In-Hyun Lee ◽  
Eunhye Lee ◽  
Jinho Park ◽  
Sangyong Jon
Keyword(s):  
Drug Delivery ◽  
Ph Sensitive ◽  
Potential Drug ◽  
Delivery Vehicle ◽  
Drug Delivery Vehicle ◽  
Polymer Nanospheres ◽  
Ph Sensitive Polymer

Pyrrhocoricin as a potential drug delivery vehicle for Cryptosporidium parvum

2008 ◽  
Vol 119 (2) ◽  
pp. 301-303 ◽  
Author(s):  
Annika Boxell ◽  
Stephanie Hui Chin Lee ◽  
Ryan Jefferies ◽  
Paul Watt ◽  
Richard Hopkins ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Cryptosporidium Parvum ◽  
Potential Drug ◽  
Delivery Vehicle ◽  
Drug Delivery Vehicle

Hollow chitosan-alginate multilayer microcapsules as drug delivery vehicle: doxorubicin loading and in vitro and in vivo studies

2007 ◽  
Vol 3 (1) ◽  
pp. 63-74 ◽  
Author(s):  
Qinghe Zhao ◽  
Baosan Han ◽  
Zhaohai Wang ◽  
Changyou Gao ◽  
Chenghong Peng ◽  
...  
Keyword(s):  
Drug Delivery ◽  
In Vivo Studies ◽  
Delivery Vehicle ◽  
Drug Delivery Vehicle

In vitro analysis of the TAT protein transduction domain as a drug delivery vehicle in protozoan parasites

2008 ◽  
Vol 118 (3) ◽  
pp. 303-307 ◽  
Author(s):  
Stephanie Hui Chin Lee ◽  
Ryan Jefferies ◽  
Paul Watt ◽  
Richard Hopkins ◽  
Frank Sotzik ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Protein Transduction ◽  
Protein Transduction Domain ◽  
Tat Protein ◽  
Protozoan Parasites ◽  
Delivery Vehicle ◽  
Drug Delivery Vehicle ◽  
Vitro Analysis ◽  
In Vitro Analysis

Hollow Chitosan-Alginate Multilayer Microcapsules as Drug Delivery Vehicle: Doxorubicin Loading and in vitro and in vivo Studies

2017 ◽  
pp. 317-345
Author(s):  
Qinghe Zhao ◽  
Baosan Han ◽  
Zhaohai Wang ◽  
Changyou Gao ◽  
Chenghong Peng ◽  
...  
Keyword(s):  
Drug Delivery ◽  
In Vivo Studies ◽  
Delivery Vehicle ◽  
Drug Delivery Vehicle

Radical Cross-Linked Albumin Microspheres as Potential Drug Delivery Systems: Preparation and In Vitro Studies

Drug Delivery ◽  
2005 ◽  
Vol 12 (4) ◽  
pp. 229-234 ◽  
Author(s):  
F. Iemma ◽  
U. G. Spizzirri ◽  
F. Puoci ◽  
R. Muzzalupo ◽  
S. Trombino ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
In Vitro Studies ◽  
Potential Drug ◽  
Albumin Microspheres

N-Methyl-2-Pyrrolidone Is a Biologically Active Thalidomide Subunit with In Vivo anti-Myeloma Properties

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 4082-4082
Author(s):  
Jake Shortt ◽  
Andy Hsu ◽  
Geoffrey M Matthews ◽  
Marta Chesi ◽  
P.Leif Bergsagel ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Cell Line ◽  
Serum Protein ◽  
Median Survival ◽  
Nk Cell ◽  
Total Serum ◽  
Delivery Vehicle ◽  
Drug Delivery Vehicle

Abstract Abstract 4082 N-methyl-2-pyrrolidone (NMP) is considered an inert drug delivery vehicle that is widely used as an industrial organic solvent. NMP is found in a range of pharmaceutical preparations and bio-prosthetic cements. In particular, NMP is used to solubilize kinase inhibitors for pre-clinical testing in experimental mice. The Vk*MYC transgenic mouse is a model of multiple myeloma (MM) that recapitulates the human disease. We have adapted Vk*MYC MM using a syngeneic transplant approach to shorten latency and facilitate testing of novel therapeutics. In this model, we noted delayed disease progression and improved survival in NMP treated mice compared to alternative vehicle controls. To confirm this observation, matched cohorts of mice bearing monoclonal kappa-secreting MM were treated with 20% NMP/80% polyethylene glycol (PEG) (n = 13), PEG alone (n = 10) or PBS (n = 7) at 100uL per 20g mouse daily p.o. Mice were monitored by serial serum protein electrophoresis and quantitative kappa immunoglobulin (IgK) estimation. At the commencement of therapy, cohorts were well matched for disease burden; mean M-spikes 12%, 14% and 14% of total serum protein for NMP, PBS and PEG respectively (p=0.58 NMP vs. PBS, p=0.68 NMP vs. PEG). After 28d treatment, NMP-treated mice had lower paraproteinemia compared to PBS and PEG controls (mean M-spike NMP 31%, PBS 42% and PEG 40%; p < 0.05 NMP vs. PBS or PEG), with concordant suppression of IgK (NMP 18g/L vs. PBS 39g/L, p<0.05). Survival in NMP-treated mice was also significantly longer than that in PBS-treated controls (median survival 50d and 40d respectively; p<0.05 log rank). Survival of PEG-only treated mice did not differ from PBS controls (median survival 39.5d; p=0.49). We compared the structure of NMP to known MM therapeutics, revealing that NMP is a subunit of thalidomide and its analogues. We next tested NMP for cytotoxicity and immune-modulatory drug (IMiD) activity in vitro. NMP (1uM – 10mM) was not directly cytotoxic to healthy donor peripheral blood mononuclear cells (PBMCs) or the U266 myeloma cell line. However, treatment of PBMC with 10uM NMP significantly enhanced NK cell cytotoxicity against the NK cell-sensitive target cell line K562 from 26% to 42% (p < 0.05). Further, NMP favored a Th-1 cytokine profile without directly altering the frequency of CD4, CD8, NK or regulatory T cell subsets in vitro. As compared to the IMiD lenalidomide, NMP inhibited TNF-a production from LPS stimulated monocytes. Given the IMiD-like effects of NMP, we assessed its ability to alter the expression of NK cell ligands on myeloma targets. NMP upregulated both NKG2D and DNAM-1 ligands (MIC-A, MIC-B, ULBP-1, ULBP-2 and CD155) on U266 cells, thereby enhancing the NK cell mediated lysis of the U266 cell line. Our results demonstrate the in vivo anti-myeloma activity and IMiD-like properties of NMP, indicating that it is a putative active thalidomide subunit. The detection of IMiD-like activity was facilitated by a sensitive, immune competent MM model. NMP should no longer be considered inert for the purposes of drug delivery. These findings mandate re-evaluation of drug efficacy data where NMP has been used as the drug delivery vehicle, particularly in immune-competent cancer models. Our findings with NMP may allow the development of new IMiDs. Finally, occupational or iatrogenic exposure to NMP should be further assessed as a potential risk for immunologically mediated adverse effects. Disclosures: No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document